Implants

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates...

IMPLANET will hold an Extraordinary General Meeting on November 16, 2023, and announces the implementation of short-term financing of a maximum net amount of €1.0 million in the form of a bond issue

Insider information: BBS-Bioactive Bone Substitutes Plc appoints Juliusz Rakowski as new CEO as BBS prepares for the commercial phase

BBS-Bioactive Bone Substitutes Plc, Company Announcement, Insider Information, 3 October 2023 at 4.00 p.m. (EET) Insider information: BBS-Bioactive Bone Substitutes...

error: Content is protected !!